i tuoi badge Intervallo 52 sett. $1–$3 89% of range Rating Analisti BUY 14 analysts Prezzo Obiettivo $2 P/E -6.2 ROE -929.3% Margine di Profitto Netto -82.5%

PACB Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03
Prezzo $2.54
Capitalizzazione di Mercato (MRQ) $789M
P/E (TTM) -6.2
EPS (TTM) $-0.41
Ricavi (TTM) $159M
ROE (TTM) -929.3%
Intervallo 52 sett. $1–$3

PACB Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04
intervallo
barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Informazioni su Pacific Biosciences of California, Inc. - Common Stock Panoramica della società da Wikipedia

05 · wikidata

Pacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

History

The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees.

It began under the name Nanofluidics, Inc. The company raised nearly US$400,000,000 in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.

The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013.

Leadership

In 2004, Kleiner Perkins entrepreneur-in-residence Hugh Martin became CEO. On 6 January 2012 board member Michael Hunkapiller, PhD assumed the role of CEO. Hunkapiller retired in September 2020, and was replaced by chairman of the board Christian Henry. Henry was a former executive VP and chief commercial officer of Illumina before joining the board at PacBio in July 2018.

Illumina: attempted acquisition

On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019. In December 2019, the Federal Trade Commission sued to block the acquisition. The deal was abandoned with an announcement on 2 January 2020. Illumina further agreed to pay Pacific Biosciences a $98 million US termination fee plus previously agreed upon deal extension payments of $22 million US in February and $6 million US in March 2020.

Sequencing technology

Sequencing instruments

The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. A new version of the sequencer was released in April 2013 it produced longer sequence reads and higher throughput than the original RS instrument. The RS instrument will officially be supported until the end of 2021. In September 2015, the company released a new sequencing instrument, the Sequel System, with increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II. Subsequently, in October 2022, PacBio launched a new sequencing system, which can sequence 1,300 human genomes per year as compared to 86 per year of the previous PacBio sequencing machines.

Reagents and SMRT Cells

To use either instrument, customers must also purchase reagent packs for DNA preparation and sequencing and small consumables called "SMRT Cells." Cells for early forms of the sequencer are slightly less than one-centimeter square and contains tens of thousands of zero-mode waveguides, whereas newer systems have a higher density of cells and contain 25 million zero-mode waveguides (ZMWGs), allowing for faster DNA sequencing.

Software and applications

Their secondary analysis bioinformatics product for the RS, called “SMRT Analysis”, was open source. For the Sequel system the secondary analysis software was reorganized as the "SMRT Link" application. In 2013, the company released new bioinformatics tools for automated genome assembly (HGAP) and finishing (Quiver).

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreHealthcare industriaLife Sciences Tools & Services dipendenti485 paeseUS

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06
Ricavi$160M
2016-12-31 → 2025-12-31
EPS$-1.82
2018-12-31 → 2025-12-31
Flusso di cassa libero$-114M
2016-12-31 → 2025-12-31
Margine netto-82.5%
2016-12-31 → 2025-12-31
Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica Tendenza 5 anni PACB media 5 anni Mediana dei peer Verdetto
P/E (TTM) -6.2media 5 anni ≈-7.8 ≈-7.8 · ·
P/S (TTM) 5.0media 5 anni ≈13.8 ≈13.8 4.6 Sottovalutato
P/B (MRQ) -23.8media 5 anni ≈23.9 ≈23.9 · ·
Prezzo / FCF (TTM) -6.4media 5 anni ≈-12.5 ≈-12.5 · ·
Prezzo / Flusso di cassa (TTM) -6.7media 5 anni ≈-13.1 ≈-13.1 · ·
Prezzo / Valore contabile tangibile (MRQ) -17.1 · · ·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14
Sorpresa media -97.7%
Prossimo report Nov 03, 2026
PeriodoRapportoEPS ActualEPS StimatoSorpresa
30 Giugno 2026 Ago 3, 2026 $-0.14 $-0.13 -7.9%
31 Marzo 2026 $-0.12 $-0.14 12.7%
31 Dicembre 2025 $-0.12 $-0.15 20.3%
30 Settembre 2025 $-0.13 $-0.15 16.1%
30 Giugno 2025 $-0.14 $-0.17 19.3%
31 Marzo 2025 $-1.44 $-0.19 -646.9%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15
Conto Economico 17
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue $160M$154M$201M$128M$131M$79M$91M$79M$93M$91M$93M$61M
Cost of Revenue $114M$117M$148M$79M$72M$46M$56M$54M$59M$47M$39M$37M
Gross Profit $46M$37M$53M$49M$59M$33M$35M$25M$35M$44M$53M$23M
R&D Expense $97M$135M$187M$193M$113M$64M$60M$63M$65M$68M$60M$48M
SG&A Expense $141M$175M$170M$161M$124M$73M$75M$63M$59M$48M$45M$38M
Operating Expenses $600M$512M$387M$356M$269M$137M$135M$126M$124M$115M$83M$86M
Operating Income $-554M$-474M$-334M$-307M$-210M$-104M$-101M$-101M$-90M$-71M$-29M$-63M
Interest Expense ··$14M$15M$13M$267.0K$3M$2M$3M$3M$3M$3M
Other Non-op $15M$24M$33M$8M$93.0K$2M$1M$848.0K$516.0K$103.0K$364.0K$-478.0K
Pretax Income $-546M$-310M$-318M$-314M$-275M$29M$-84M·····
Income Tax $318.0K$316.0K$-11M$0$-94M·······
Net Income $-546M$-310M$-307M$-314M$-181M$29M$-84M$-103M$-92M$-74M$-32M$-66M
EPS (Basic) $-1.82$-1.13$-1.21$-1.40$-0.89$0.18$-0.55$-0.76····
EPS (Diluted) $-1.82$-1.59$-1.21$-1.40$-0.89$0.17$-0.55$-0.76····
Shares (Basic) 299,959,000274,488,000253,629,000224,550,000204,136,000165,187,000152,527,000135,094,000····
Shares (Diluted) 299,959,000288,366,000253,629,000224,550,000204,136,000174,970,000152,527,000135,094,000····
EBITDA $-554M$-474M$-334M$-307M$-210M$-104M$-101M$-94M$-81M$-67M$-25M$-59M
Stato Patrimoniale 30
Metrica Tendenza 202520242023202220212020201920182017201620152014
Cash & Equivalents $64M$55M$180M$325M$461M$82M$30M$19M$17M$17M$34M$36M
Short-term Investments $216M$335M$452M$447M$584M$237M$19M$84M$46M$55M$49M$65M
Receivables $35M$28M$37M$19M$24M$17M$15M$9M$13M$11M$5M$3M
Inventory $49M$59M$57M$50M$25M$14M$13M$18M$23M$16M$11M$11M
Prepaid Expense $11M$19M$17M$10M$7M$5M$3M$3M$2M$10M$12M$2M
Other Current Assets ········$931.0K$476.0K$741.0K$107.0K
Current Assets $375M$496M$742M$852M$1.10B$356M$81M$132M$102M$109M$111M$118M
PP&E (Net) $24M$31M$36M$42M$33M$25M$30M$34M$38M$15M$9M$7M
PP&E (Gross) $117M$112M$111M$107M$89M$75M$74M$71M$70M$52M$42M$37M
Accum. Depreciation $92M$82M$75M$65M$56M$50M$44M$37M$32M$37M$34M$30M
Goodwill $318M$318M$462M$410M$410M·······
Intangibles $15M$390M$457M$410M$411M·······
Other Non-current Assets $9M$9M$13M$11M$1M$43.0K$42.0K$43.0K$45.0K$10M$8M$29.0K
Total Assets $784M$1.26B$1.75B$1.77B$2.01B$414M$148M$170M$144M$138M$131M$124M
Accounts Payable $21M$17M$15M$12M$11M$4M$8M$7M$9M$8M$5M$6M
Accrued Liabilities $34M$23M$46M$33M$36M$17M$13M$13M$13M$17M$16M$11M
Short-term Debt ·$0$490.0K$2M$2M·$16M·····
Current Liabilities $73M$66M$95M$263M$72M$39M$49M$27M$29M$34M$38M$31M
Capital Leases $57M$15M$32M$41M$50M$38M$42M····$2M
Other Non-current Liabilities $0$546.0K$751.0K$1M$3M$752.0K···$2M$1M$2M
Total Liabilities $779M$754M$1.04B$1.20B$1.22B$78M$93M$56M$58M$53M$58M$69M
Long-term Debt ···$897M$896M·$16M$15M$14M$16M·$14M
Total Debt ·$0$490.0K$2M$2M·$16M·····
Common Stock $302.0K$294.0K$268.0K$227.0K$221.0K$192.0K$153.0K$150.0K$116.0K$93.0K$80.0K$74.0K
Paid-in Capital $2.70B$2.65B$2.54B$2.10B$2.01B$1.37B$1.12B$1.10B$966M$872M$787M$736M
Retained Earnings $-2.70B$-2.15B$-1.84B$-1.53B$-1.22B$-1.04B$-1.07B$-982M$-880M$-788M$-713M$-681M
AOCI $457.0K$422.0K$219.0K$-5M$-1M$85.0K$5.0K$-36.0K$-32.0K$5.0K$-7.0K$9.0K
Stockholders' Equity $5M$507M$701M$563M$791M$335M$55M$114M$86M$85M$74M$55M
Liabilities + Equity $784M$1.26B$1.75B$1.77B$2.01B$414M$148M$170M$144M$138M$131M$124M
Shares Outstanding 301,956,000294,418,000267,744,000226,505,000220,978,000192,294,000153,119,000150,244,000116,277,00092,677,00079,983,00073,927,000
Flusso di cassa 16
Metrica Tendenza 202520242023202220212020201920182017201620152014
D&A ·······$7M$8M$4M$4M$4M
Stock-based Comp $42M$71M$72M$79M$73M$18M$16M$23M$20M$20M$14M$10M
Deferred Tax $-546.0K$-205.0K$-11M$0$-94M·······
Amort. of Intangibles $369M$27M$8M$913.0K$0$0$0·····
Restructuring ·$13M··········
Other Non-cash ·······$6M$-4M$-17M$-34M$528.0K
Operating Cash Flow $-111M$-206M$-259M$-263M$-111M$20M$-78M$-66M$-68M$-68M$-48M$-51M
CapEx $3M$6M$9M$17M$6M$1M$3M$2M$10M$8M$3M$2M
Investing Cash Flow $115M$124M$5M$116M$-679M$-219M$62M$-38M$-2M$-15M··
Stock Issued $0$0$189M$0$32M$46M$9M$10M$9M$8M$7M$4M
Net Stock Activity $0$0$15M$11M$32M$46M$9M$10M$9M$8M$7M$4M
Financing Cash Flow $3M$-43M$109M$10M$1.17B$252M$27M$107M$69M$66M··
Net Change in Cash $8M$-125M$-146M$-138M$380M···$-258.0K$-17M$-3M$10M
Taxes Paid $481.0K$256.0K$140.0K·········
Free Cash Flow $-114M$-212M$-268M$-280M$-117M$18M$-81M$-68M$-78M$-76M$-51M$-53M
Levered FCF ··$-282M·$-125M·······
Redditività 8
Metrica Tendenza 202520242023202220212020201920182017201620152014
Gross Margin 28.6%24.2%26.3%38.2%45.1%41.3%38.0%31.9%37.1%48.7%57.6%38.6%
Operating Margin -346.1%-308.0%-166.8%-239.4%-161.2%-132.3%-110.6%-128.4%-96.1%-78.5%-31.4%-103.7%
Net Margin -341.5%-201.2%-153.0%-244.9%-138.8%37.3%-92.6%-130.4%-98.6%-82.0%-34.2%-109.2%
Pretax Margin -341.3%-201.0%-158.7%-244.9%-210.6%·······
EBITDA Margin -346.1%-308.0%-166.8%-239.4%-161.2%-132.3%-110.6%-119.3%-87.0%-74.3%-27.4%-96.8%
ROA -53.4%-20.6%-17.5%-16.7%-15.0%10.5%-52.9%-65.2%-65.4%-55.3%-24.8%-50.7%
ROE -1634.9%-64.6%-41.9%-52.8%-22.2%12.7%-158.8%-83.4%-108.0%-94.0%-49.3%-106.6%
ROIC -10360.5%-93.7%-46.0%·-17.5%·······
Liquidità e Solvibilità 4
Metrica Tendenza 202520242023202220212020201920182017201620152014
Current Ratio 5.17.57.83.215.49.21.64.93.53.22.93.7
Quick Ratio 4.36.37.03.014.98.71.34.12.72.52.33.3
Debt / Equity ·0.00.00.00.0·0.3·····
Interest Coverage ··-23.3-20.9-16.8-391.0-38.5-41.7-30.7-22.0-10.0-22.2
Efficienza 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Asset Turnover 0.20.10.10.10.10.30.60.50.70.70.70.5
Inventory Turnover 2.12.02.82.13.73.43.62.63.03.53.53.5
Receivables Turnover 5.14.87.26.06.44.97.67.17.510.921.419.7
Per Azione 6
Metrica Tendenza 202520242023202220212020201920182017201620152014
Book Value / Share $0.02$1.72$2.62$2.49$3.58$1.74$0.36$0.76$0.74$0.91$0.92$0.74
Revenue / Share $0.53$0.53$0.79$0.57$0.64$0.45······
Cash Flow / Share $-0.37$-0.71$-1.02$-1.17$-0.54$0.11······
Cash / Share $0.21$0.19$0.67$1.44$2.08$0.42$0.19$0.13$0.14$0.18$0.42$0.49
Dividend / Share $0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
EPS (TTM) $-1.82$-1.59$-1.21$-1.40$-0.89$0.17$-0.55$-0.76····
Tassi di Crescita 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue YoY 3.9%-23.2%56.3%-1.7%65.4%·······
Revenue CAGR 3Y 7.6%5.7%36.5%·········
Revenue CAGR 5Y 15.2%···········
Valutazione (TTM) 14
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue TTM $160M$154M$201M$128M$131M$79M$91M$79M$93M$91M$93M$61M
Net Income TTM $-546M$-310M$-307M$-314M$-181M$29M$-84M$-103M$-92M$-74M$-32M$-66M
Market Cap $565M$539M$2.63B$1.85B$4.52B$4.99B$787M$1.11B$307M$352M$1.05B$580M
Enterprise Value ·$149M$2.00B$1.08B$3.48B·$754M·····
P/E -1.0-1.2-8.1-5.8-23.0152.6-9.3-9.7····
P/S 3.53.513.114.434.663.28.714.13.33.911.39.6
P/B 105.61.13.73.35.714.914.39.73.64.214.310.5
P / Tangible Book ·····14.9······
P / Cash Flow -5.1-2.6-10.1-7.0-40.7255.8-10.0-16.7-4.5-5.2-21.9-11.3
P / FCF -5.0-2.5-9.8-6.6-38.6270.2-9.7-16.3-3.9-4.6-20.6-10.9
EV / EBITDA ·-0.3-6.0-3.5-16.5·-7.5·····
EV / FCF ·-0.7-7.4-3.9-29.7·-9.3·····
EV / Revenue ·1.010.08.426.7·8.3·····
Earnings Yield -97.3%-86.9%-12.3%-17.1%-4.3%0.66%-10.7%-10.3%····

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16
Metrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ricavi $160M $154M $201M $128M $131M
Margine Lordo % 28.6% 24.2% 26.3% 38.2% 45.1%
Margine Operativo % -346.1% -308.0% -166.8% -239.4% -161.2%
Utile netto $-546M $-310M $-307M $-314M $-181M
EPS Diluito $-1.82 $-1.59 $-1.21 $-1.40 $-0.89

Proprietari istituzionali (13F) 244 filer · $360.0M totale · Aggiornato al 30 Giugno 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 244
Valore detenuto $360.0M
Nuove posizioni 24
Posizioni chiuse 28
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni Posizioni chiuse Aumentato Diminuito Variazione netta delle azioni
24 (-30 vs trimestre precedente) 28 (-2 vs trimestre precedente) 72 (+14 vs trimestre precedente) 80 (+4 vs trimestre precedente) +4.3M

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione Valore Azioni % di 13F tracciati Tipo
BlackRock, Inc. $54.330.444 32.339.550 15,09% Azioni
ARK Investment Management LLC $50.032.778 29.781.416 13,90% Azioni
SOFTBANK GROUP CORP. $34.358.638 20.451.570 9,54% Azioni
VANGUARD GROUP INC $31.859.776 17.037.314 8,85% Azioni
VANGUARD CAPITAL MANAGEMENT LLC $22.508.529 13.397.934 6,25% Azioni
GEODE CAPITAL MANAGEMENT, LLC $12.782.429 7.606.518 3,55% Azioni
Sumitomo Mitsui Trust Group, Inc. $10.096.321 6.009.715 2,80% Azioni
Amova Asset Management Americas, Inc. $10.036.224 6.009.715 2,79% Azioni
STATE STREET CORP $10.014.774 5.961.175 2,78% Azioni
Point72 Asset Management, L.P. $8.042.664 4.787.300 2,23% Azioni
TWO SIGMA INVESTMENTS, LP $7.127.566 4.242.599 1,98% Azioni
D. E. Shaw & Co., Inc. $7.069.686 4.208.146 1,96% Azioni
MILLENNIUM MANAGEMENT LLC $6.656.903 3.962.442 1,85% Azioni
Point72 (DIFC) Ltd $5.465.775 4.270.137 1,52% Azioni
GOLDMAN SACHS GROUP INC $5.426.210 3.229.887 1,51% Azioni
CITADEL ADVISORS LLC $4.781.117 2.845.903 1,33% Azioni
VANGUARD PORTFOLIO MANAGEMENT LLC $4.488.819 2.671.916 1,25% Azioni
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $4.455.861 2.652.298 1,24% Azioni
NORTHERN TRUST CORP $3.952.681 2.352.786 1,10% Azioni
VANGUARD FIDUCIARY TRUST CO $3.675.213 2.187.627 1,02% Azioni
SUSQUEHANNA INTERNATIONAL GROUP, LLP $3.577.162 2.129.263 0,99% Azioni
Longaeva Partners L.P. $3.558.628 2.118.231 0,99% Azioni
IQ EQ FUND MANAGEMENT (IRELAND) Ltd $2.846.837 1.694.546 0,79% Azioni
Birchview Capital, LP $2.268.000 1.350.000 0,63% Azioni
BANK OF AMERICA CORP /DE/ $2.264.860 1.348.131 0,63% Azioni
Invesco Ltd. $2.179.114 1.297.091 0,61% Azioni
AQR CAPITAL MANAGEMENT LLC $2.178.430 1.296.684 0,61% Azioni
Nuveen, LLC $1.718.830 1.023.113 0,48% Azioni
RENAISSANCE TECHNOLOGIES LLC $1.623.216 966.200 0,45% Azioni
BOURNE LENT ASSET MANAGEMENT INC $1.584.332 943.055 0,44% Azioni
TWO SIGMA ADVISERS, LP $1.547.425 827.500 0,43% Azioni
HHLR ADVISORS, LTD. $1.543.739 918.892 0,43% Azioni
UBS Group AG $1.500.475 893.140 0,42% Azioni
Universal- Beteiligungs- und Servicegesellschaft mbH $1.358.616 808.700 0,38% Azioni
Bank of New York Mellon Corp $1.289.512 767.567 0,36% Azioni
DIMENSIONAL FUND ADVISORS LP $1.277.135 759.783 0,35% Azioni
Casdin Capital, LLC $1.215.929 723.767 0,34% Azioni
TUDOR INVESTMENT CORP ET AL $1.150.308 684.707 0,32% Azioni
XTX Topco Ltd $1.073.322 638.882 0,30% Azioni
Numerai GP LLC $1.044.068 621.469 0,29% Azioni
CARRET ASSET MANAGEMENT, LLC $1.008.235 600.140 0,28% Azioni
Man Group plc $1.003.521 597.334 0,28% Azioni
Russell Investments Group, Ltd. $1.002.694 596.843 0,28% Azioni
Balyasny Asset Management L.P. $948.090 564.339 0,26% Azioni
PEAK6 LLC $933.327 555.552 0,26% Azioni
Vestmark Advisory Solutions, Inc. $803.384 478.205 0,22% Azioni
MORGAN STANLEY $802.664 477.776 0,22% Azioni
ArrowMark Colorado Holdings LLC $786.882 468.382 0,22% Azioni
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. $741.954 441.639 0,21% Azioni
SUSQUEHANNA INTERNATIONAL GROUP, LLP $673.008 400.600 0,19% Opzione Put

Mostra tutti i 244 proprietari istituzionali →

Attivisti e proprietari del 5%+ 1 partecipazione

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante Depositato Partecipazione Stato Scopo Deposito
Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, Alec N. Litowitz ×3 depositi 29 Agosto 2019 · Deposito iniziale · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 30 insider · 6 dirigenti · 11 direttori

19
Insider Ruolo Ultima attività Azioni possedute Acquisti 12m Vendite 12m Netto 12m
Mark Van Oene President & CEO 17 Agosto 2026 S 2.705.853 0 4 $-335.122
Susan K Barnes EVP, CFO and PAO 19 Febbraio 2020 S 874.812 0 0 $0
James Michael Phillips SVP, Research & Development 24 Marzo 2020 S 249.220 0 0 $0
Kevin P Corcoran SVP, Market Development 24 Novembre 2017 M 158.174 0 0 $0
Michael Glynn Chief Commercial Officer 15 Febbraio 2012 A · 0 0 $0
Stephen W Turner VP & Chief Technology Officer 11 Luglio 2011 J 1.093.063 0 0 $0
Christopher Gibson Direttore 03 Giugno 2026 A 111.386 0 0 $0
Hannah Valantine Direttore 03 Giugno 2026 A 22.821 0 0 $0
William W. Ericson Direttore 03 Giugno 2026 A 41.616 0 0 $0
Christopher M Smith Direttore 03 Giugno 2026 A 54.099 0 0 $0
Marshall Mohr Direttore 03 Giugno 2026 A 132.821 0 0 $0
Randall S Livingston Direttore 03 Giugno 2026 A 22.821 0 0 $0
Kathy Ordonez Direttore 03 Giugno 2026 A 403.037 0 0 $0
John F Milligan Direttore 03 Giugno 2026 A 132.821 0 0 $0
David B. Singer Direttore 13 Giugno 2012 A · 0 0 $0
Susan E Siegel Direttore 13 Giugno 2012 A 65.000 0 0 $0
Hugh C Martin Direttore 03 Febbraio 2012 M 342.458 0 0 $0
James R Gibson II · 01 Aprile 2026 S 1.245.663 0 1 $-120.813
Michele Farmer · 03 Marzo 2026 S 305.948 0 3 $-84.510
Christian O Henry · 03 Marzo 2026 S 3.581.813 0 3 $-772.728
Lucy Shapiro · 04 Giugno 2025 A 22.821 0 0 $0
Susan G. Kim · 30 Settembre 2024 S 695.654 0 0 $0
Jeff Eidel · 19 Agosto 2024 S 869.730 0 0 $0
David W Meline · 18 Giugno 2024 A 57.116 0 0 $0
David Botstein · 24 Maggio 2023 A 0 0 0 $0
Peter Fromen · 02 Marzo 2022 A 190.280 0 0 $0
Michael Hunkapiller · 26 Febbraio 2021 M 848.405 0 0 $0
Eric Schaefer · 22 Febbraio 2021 S 88.474 0 0 $0
BYERS BROOK H · 17 Maggio 2016 A 110.504 0 0 $0
Brian B Dow · 02 Marzo 2015 P 18.119 0 0 $0

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

Proprietà ETF Posseduti da 21 ETF

20

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.

Fondo Peso Unità Aggiornato al Fonte
ARKG · ARK ETF Trust 0,96% 10.630.263 NS 31 Luglio 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0,91% 88.548 SH 01 Ottobre 2026 Giornaliero
IDNA · iShares Trust 0,35% 711.655 SH 11 Settembre 2026 Giornaliero
ARKK · ARK ETF Trust 0,32% 12.810.378 NS 31 Luglio 2026 N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust 0,09% 1.001.721 SH 01 Ottobre 2026 Giornaliero
IBBQ · Invesco Exchange-Traded Fund Trust … 0,05% 21.993 SH 01 Ottobre 2026 Giornaliero
VTWG · VANGUARD SCOTTSDALE FUNDS 0,03% 280.941 SH 19 Agosto 2026 Giornaliero
IBB · iShares Trust 0,03% 2.192.352 SH 11 Settembre 2026 Giornaliero
IWO · iShares Trust 0,02% 2.473.318 SH 11 Settembre 2026 Giornaliero
RSSL · Global X Funds 0,01% 134.834 NS 31 Luglio 2026 N-PORT
IWM · iShares Trust 0,01% 7.217.251 SH 11 Settembre 2026 Giornaliero
VXF · VANGUARD INDEX FUNDS 0,01% 3.579.782 SH 19 Agosto 2026 Giornaliero
VTWO · VANGUARD SCOTTSDALE FUNDS 0,01% 1.624.029 SH 19 Agosto 2026 Giornaliero
VHT · VANGUARD WORLD FUND 0,01% 727.094 SH 19 Agosto 2026 Giornaliero
ITOT · iShares Trust 0,00% 431.328 SH 11 Settembre 2026 Giornaliero
IWV · iShares Trust 0,00% 69.680 SH 09 Settembre 2026 Giornaliero
VTI · VANGUARD INDEX FUNDS 0,00% 9.535.565 SH 19 Agosto 2026 Giornaliero
VTWV · VANGUARD SCOTTSDALE FUNDS 0,00% 17.047 SH 19 Agosto 2026 Giornaliero
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 22.805 SH 19 Agosto 2026 Giornaliero
DFAC · Dimensional ETF Trust 0,00% 8.144 NS 31 Luglio 2026 N-PORT
IWN · iShares Trust · 207.024 SH 11 Settembre 2026 Giornaliero

PACB Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21
rating · 14 analisti COMPRA
Target mediano $2.00 -21,3%
4 28,6% Acquisto forte
5 35,7% Compra
4 28,6% Mantieni
1 7,1% Vendi
0 0,0% Vendita forte

Target Price a 12 Mesi

7 analisti · 2026-10-02

Target medio $2.16 -15,1%

Ora Prezzo attuale $2.54
Basso$1.25 Media$2.16 Alto$3.00

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker Capitalizzazione di Mercato P/E Rev YoY Margine Netto ROE Margine lordo
PACB $565M -1.0 3.9% -341.5% -1634.9% 28.6%
BLFS · -241.8 28.9% · · ·
PSNL $816M -8.7 -17.7% -116.7% -36.0% ·
AZTA $1.32B -23.5 3.5% -9.4% -3.3% 45.5%
CYRX $479M 6.9 12.4% 44.4% 15.3% 47.1%
DNA $484M -1.5 -25.1% -183.8% -55.8% ·
CTKB $649M 505.0 0.52% -33.0% -18.5% 51.8%
MLAB $489M 73.1 3.4% 2.7% 3.7% 63.5%
OABI · · · · · ·
TKNO $204M -11.9 7.3% -42.6% -23.8% 33.2%
QSI · · · · · ·

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

Fonte: SEC 10-Q depositato Ago 6, 2026